Abstract
Azunol® ST contains 5mg water soluble Azunol in one tablet, and in this study Azunol® ST was administered into the nasal cavity of 67 patient (nasal group) and into the labiogingival region of the upper jaw in 47 patients (oral group) with common cold in the early stage and the effects were compared to non-administration in 111 patients (control group). In all patients in the nasal and oral groups, one tablet was given before bed. The following results were obtained:1) The rate of desease of common cold did not significantly differ among the three groups. (x2 test)2) In the nasal and oral groups, the rate of preventing progression was higher than in the control group (P<0.05). (nasal group 90±22%, oral group 91±20%, control group 76±38%)3) The affected period was significantly shorter in the nasal group than in the control group. (P<0.05), but there was no significant difference between the nasal and oral groups or between the oral and control groups (The period of affection: nasal group 4.29±3.53 days, oral group 6.45±5.84 days, control group 8.06±6.11 days)4) When the initial symptom was epipharyngalgia, the administration of Azunol® ST in the nasal cavity completely prevented (100%) the progression of symptoms, however, the rate of preventing progression was not significantly different between the oral (61%) and control groups (70%).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
